Zaynich (cefepime and zidebactam)
Wockhardt Bio AG
ApprovedMay 29, 2026
Marketer take
A new IV beta-lactam combination for cUTI, so hospital ID physicians, pharmacists and stewardship committees decide whether it is reserved for resistant organisms.
- Sponsor company
- Wockhardt Bio AG
- Indication
- To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms
- Therapeutic area
- Infectious disease
- Event
- FDA approval
- Date
- May 29, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?